David Amesellem

Analysts David Amesellem and Michael Dinerman at Piper Jaffray have maintained their Overweight rating on Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP). Analysts say that prescription (Rx) data since the late March FDA approval shows a clear acceleration in Rx growth. Analysts believe that the strong...